Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Provides Portfolio and Business Update GlobeNewswire July 01, 2025 Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infusion VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a […]